Boston Scientific hesitates to release full safety results for Watchman heart implant

Wed, 03/06/2013 - 1:27pm
Mass Device

Some Wall Street analysts are wary of Boston Scientific's decision to hold back some of the safety results from a trial of its Watchman stroke prevention implant.

Boston Scientific's Watchman heart implant

Officials at Boston Scientific (NYSE:BSX) announced this week that they would reveal only limited patient safety results when they present data from a clinical trial of the Watchman stroke prevention implant at the American College of Cardiology conference this week.

The Massachusetts-based medical device giant revealed in a press release that it plans to "present the acute procedural safety results of the PREVAIL clinical trial," keeping 2 other safety endpoints under wraps for the time being.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.